FY2023 · ended Dec 31, 2023 · Revenue $39,518, +345.3% YoY · Filed Apr 16, 2024
Axim Biotechnologies, Inc. (AXIM) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2023, which ended Dec 31, 2023, it reported revenue of $39,518 and a net loss of $8.1 million. Free cash flow was -$1.0 million. As of Jun 30, 2024 it held $6,044 in cash and investments and $6.0 million in total debt.
Revenue (TTM)
$92,898
+257.9% vs year-ago TTM
Net income (TTM)
$-4.14M
+56.1% vs year-ago TTM
Operating cash flow (TTM)
$-758,995
+46.6% vs year-ago TTM
Free cash flow
$-1.03M
+49.8% vs prior year
EPS
$-0.04
+0.0% vs prior year
Dividend per share
None
Shares outstanding
278.43M
+24.5% vs prior year
Net cash
$-5.96M
as of Jun 30, 2024
Operating margin
-2490.3%
FY 2024
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- AXIM (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- NV
- Headquarters
- San Diego, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1514946
- Former names
- AXIM INTERNATIONAL INC. (until Aug 13, 2014)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
FY 2020 Dec 31, 2020 |
FY 2019 Dec 31, 2019 |
|---|---|---|---|---|---|
| Revenue | $39,518 | $8,875 | $60,460 | $0 | $799,483 |
| Operating income | -$2.8M | -$4.7M | -$14.0M | -$4.9M | -$3.1M |
| Net income | -$8.1M | -$6.2M | -$16.0M | -$6.4M | -$6.4M |
| Diluted EPS | -$0.04 | -$0.04 | $0.12 | -$0.06 | — |
| Operating cash flow | -$1.0M | -$2.0M | -$2.5M | -$3.2M | — |
| Free cash flow | -$1.0M | -$2.1M | -$2.5M | — | — |
| Total assets | $4.1M | $4.2M | $5.3M | $11.3M | $1.7M |
| Total liabilities | $11.8M | $9.0M | $7.7M | $9.7M | $8.5M |
| Stockholders' equity | -$7.7M | -$4.8M | -$2.3M | — | — |
| Cash and investments | $156,457 | $47,282 | $452,963 | $457,181 | $725,375 |
| Total debt | $231,873 | $19,789 | $77,051 | $180 | $5,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Change in control, Officer or director change
|
Oct 15, 2024 | Oct 9, 2024 |
| 10-Q | Quarterly report | Aug 19, 2024 | Jun 30, 2024 |
| 10-Q/A | Amended quarterly report | May 22, 2024 | Mar 31, 2024 |
| 10-Q | Quarterly report | May 20, 2024 | Mar 31, 2024 |
| 10-K | Annual report | Apr 16, 2024 | Dec 31, 2023 |
| 8-K |
Current report
Material agreement, New debt
|
Mar 21, 2024 | Mar 15, 2024 |
All 306 Axim Biotechnologies, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.